DCM Foundation
Heartfelt Thanks
to our Sponsors

Natural History Study Seeks Participants with MYBPC3 Genetic Mutation

​Tenaya Therapeutics, a biotechnology company committed to discovering, developing, and delivering curative therapies that address the underlying causes of heart disease, is sponsoring a study to better understand pediatric cardiomyopathy due to the MYBPC3 mutation.

The MyClimb Natural History Study is designed to collect and evaluate information on the course of cardiomyopathy in children and adolescents <18 years of age with the MYBPC3 genetic mutation. Please CLICK HERE for more information and who to contact if you are interested in having your child participate.


Connect with us!
Facebook Instagram Twitter YouTube

Contact Us


7826 Kate Brown Drive
Dublin, Ohio 43017